Adaptive Biotechnologies Partners with Pfizer on Immune Disease Research
Adaptive Biotechnologies signs two deals with Pfizer worth up to $890M to discover rheumatoid arthritis treatments and share immune system data for AI-powered drug development.
/ 41 items
#PFE↓
FDA Memo on Vaccine Deaths Sends Moderna, Novavax Stocks Tumbling
Moderna and Novavax shares drop 5-6% after FDA's vaccine chief links COVID-19 shots to 10 children's deaths and announces stricter vaccine approval standards.
FDA Approves Keytruda + Padcev Combo for Bladder Cancer Surgery Patients
FDA approves groundbreaking Keytruda (MRK) and Padcev (PFE) combination as first perioperative treatment for muscle-invasive bladder cancer patients who can't receive chemotherapy.
Novo Nordisk Shares Jump 3% After Withdrawing from $10 Billion Metsera Bidding War
Novo Nordisk stock climbed up to 3% after the Danish drugmaker withdrew from its heated bidding war with Pfizer over obesity drug startup Metsera, citing financial discipline concerns.
Novo Nordisk Raises Bid Again for Metsera as Takeover Battle with Pfizer Heats Up
Novo Nordisk boosts its offer for obesity startup Metsera, countering Pfizer’s $86.20 per share bid. The bidding war is nearing its end as both pharma giants race to dominate the booming obesity drug market.
Moderna Lowers 2025 Revenue Forecast but Beats Q3 Expectations
Moderna cut its 2025 revenue forecast due to weak U.S. COVID-19 vaccine sales but beat Wall Street’s Q3 estimates, lifting shares premarket.